MAY 21, 2019 11:25 AM PDT

Benralizumab not effective reducing exacerbations of COPD

WRITTEN BY: Nouran Amin

According to the American Lung Association, chronic obstructive pulmonary disease (COPD) is the third leading cause of death in this country. More than often, patients go through potentially life-threatening exacerbations, including days-long flare-ups of symptoms, shortness of breath, swelling and mucus.

Now, a recent study published in the New England Journal of Medicine, shows that a drug used as a therapeutic for asthma, has failed to reduce symptoms of COPD. The drug is called benralizumab and is interleukin-5 receptor alpha-directed cytolytic monoclonal antibody that is FDA approved to treat severe eosinophilic asthma—the presence of high amounts of eosinophils (a particular type of immune cell) exacerbates the symptoms of COPD.

"COPD is a life-altering condition that causes serious long-term disability for patients," said Dr. Criner, Chair and Professor of Thoracic Medicine and Surgery at the Lewis Katz School of Medicine at Temple University, Director of the Temple Lung Center and corresponding author on the study. "Discovering treatments that prevent and/or limit exacerbations is a priority for clinicians and researchers as we seek to improve the quality of life for patients. Unfortunately benralizumab did not accomplish that objective in these studies, but the findings will inform current and future avenues of exploration for new treatments."

However, an earlier phase II trial found that benralizumab had a non-statistically significant reduction in COPD exacerbation rate for patients with eosinophilic inflammation in their airways.

"The findings in these two trials suggest that eosinophil depletion may not completely ameliorate exacerbation outcomes for patients with COPD," added Dr. Criner. "However, as one of the nation's premier lung-disease research centers, the Temple Lung Center continues to investigate alternative treatment options and offer patients access to leading-edge clinical trials."

Source: Temple Health

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
APR 22, 2020
Drug Discovery & Development
APR 22, 2020
Only 3% of COVID-19 Antibody Tests Approved by FDA
So far, only 3% of at least 90 COVID-19 antibody tests in the US have been approved by the Food and Drug Administration ...
APR 13, 2020
Drug Discovery & Development
APR 13, 2020
Experimental Drug Prevents Cancer Relapse
One of the main challenges of cancer treatments is preventing the cancer from returning again—in essence stopping ...
APR 23, 2020
Cancer
APR 23, 2020
Doctors, watch out for unexpected side effects in small clinical trials
Doctors who have patients in small-sized clinical trials that test new cancer drugs should be on the look-out for unexpe ...
MAY 13, 2020
Drug Discovery & Development
MAY 13, 2020
Fecal Transplant Helps Fight off Antibiotic Resistance
Fecal transplants work by transporting fecal matter from healthy donors to those who are less healthy. Now, a study has ...
MAY 19, 2020
Drug Discovery & Development
MAY 19, 2020
Can Chinese Drug Cure COVID-19 Without Vaccine?
Researchers at China’s Peking University have announced that they are developing a treatment capable of blocking C ...
MAY 13, 2020
Drug Discovery & Development
MAY 13, 2020
Drug Targets Off Episodes of Parkinson
A novel drug was approved by the FDA to target the “off” episodes of Parkinson disease. The drug is referred ...
Loading Comments...